Paradigm Biopharmaceuticals Ltd. (PBIGF)
OTHER OTC:PBIGF
PBIGF Stock Chart & Stats
$0.24
-$0.01(-3.72%)
At close: 4:00 PM EST
$0.24
-$0.01(-3.72%)
Day’s Range― - ―
52-Week Range$0.13 - $0.35
Previous CloseN/A
Volume2.27K
Average Volume (3M)1.65K
Market Cap
$70.84M
Enterprise Value$83.48M
Total Cash (Recent Filing)$14.66M
Total Debt (Recent Filing)$1.01M
Price to Earnings (P/E)―
Beta-0.12
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding451,772,460
10 Day Avg. Volume200
30 Day Avg. Volume1,650
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)4.53
Price to Sales (P/S)1840.42
P/FCF Ratio-6.00
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue1.38K
Enterprise Value/Gross Profit-855.55
Enterprise Value/Ebitda-2.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetExtremely low debt relative to equity provides durable financial flexibility: it reduces refinancing and interest-rate risk, gives management optionality to fund R&D or commercialization with less near-term pressure, and preserves runway when cash flows are weak.
Improving Cash OutflowsA marked reduction in cash burn in FY2025 signals tangible progress in cost control or operational efficiency. If sustained, this trend strengthens sustainability, reduces frequency/size of external raises, and materially improves the company's path toward self-funded operations.
Commercial/licensing Revenue ModelA business model combining product sales with licensing/distribution creates multiple durable revenue channels. This structural mix lets the company scale via direct sales where feasible and de-risk via licensing partnerships, supporting longer-term revenue diversification as products mature.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow implies ongoing reliance on external financing to sustain operations. Over months, this increases dilution or leverage risk, constrains strategic investments, and leaves the company vulnerable if capital markets tighten or fundraising terms worsen.
Minimal, Volatile RevenueSmall, inconsistent top-line undermines scalability and margin recovery: without stable, growing revenue the company cannot absorb fixed costs, invest in commercialization, or demonstrate predictable cash generation, making long-term profitability targets harder to achieve.
Deep Losses And Value ErosionMaterially declining equity and persistently negative ROE reflect recurring operating losses that erode shareholder capital. Over time this weakens the balance sheet, complicates capital raises, and signals structural profitability issues that threaten long-term shareholder value.
Paradigm Biopharmaceuticals News
PBIGF FAQ
What was Paradigm Biopharmaceuticals Ltd.’s price range in the past 12 months?
Paradigm Biopharmaceuticals Ltd. lowest stock price was $0.13 and its highest was $0.35 in the past 12 months.
What is Paradigm Biopharmaceuticals Ltd.’s market cap?
Paradigm Biopharmaceuticals Ltd.’s market cap is $70.84M.
When is Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date?
Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 134 days.
How were Paradigm Biopharmaceuticals Ltd.’s earnings last quarter?
Paradigm Biopharmaceuticals Ltd. released its earnings results on Feb 26, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.04.
Is Paradigm Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Paradigm Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Paradigm Biopharmaceuticals Ltd. pay dividends?
Paradigm Biopharmaceuticals Ltd. does not currently pay dividends.
What is Paradigm Biopharmaceuticals Ltd.’s EPS estimate?
Paradigm Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Paradigm Biopharmaceuticals Ltd. have?
Paradigm Biopharmaceuticals Ltd. has 451,772,460 shares outstanding.
What happened to Paradigm Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Paradigm Biopharmaceuticals Ltd. reported an EPS of -$0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5%.
Which hedge fund is a major shareholder of Paradigm Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in PBIGF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Paradigm Biopharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.63%
12-Months-Change
Fundamentals
Return on Equity
-265.55%
Trailing 12-Months
Asset Growth
-29.47%
Trailing 12-Months
Company Description
Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Technical Analysis
Amplia Therapeutics
―
Actinogen Medical
―
Dimerix Limited
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Ownership Overview
4.69% Insiders
<0.01% Other Institutional Investors
95.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---